Abstract
Sequential treatment with different tyrosine kinase inhibitors (TKIs) is one of the strategies for handling chronic myeloid leukemia (CML) in which dynamic change in Bcr-Abl kinase domain mutation is often an obstacle faced during TKI therapy. Here we report successful sequential therapy with different TKIs for the CML patient harboring V299L and E459K compound mutations. Molecular monitoring including quantitative analysis of BCR-ABL transcript level and mutation analysis were performed regularly for successful treatment. Additionally a drug-target complex was structurally modeled to investigate influence of amino acid substitutions on drug resistance, and to choose alternative TKI in sequential therapy, suggesting protein structural modeling can be useful approach in selecting alternative TKIs.
| Original language | English |
|---|---|
| Pages (from-to) | 1260-1265 |
| Number of pages | 6 |
| Journal | Leukemia Research |
| Volume | 33 |
| Issue number | 9 |
| DOIs | |
| State | Published - Sep 2009 |
Bibliographical note
Funding Information:This work was supported by a grant from the National Research Resource Bank Program of the Korea Science and Engineering Foundation of the Ministry of Science and Technology (No. R21-2002-000-00010-0) and by a grant from the Korea Health 21 R&D Project, Ministry of Health & Welfare, Republic of Korea (No. 01-PJ10-PG6-01GN16-0005).[J.M.B.]
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- BCR-ABL compound mutations
- Chronic myeloid leukemia
- Protein structural modeling
- Sequential therapy
- Tyrosine kinase inhibitor
Fingerprint
Dive into the research topics of 'Structural modeling of V299L and E459K Bcr-Abl mutation, and sequential therapy of tyrosine kinase inhibitors for the compound mutations'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver